Why the study?
Slow breathing provides therapeutic benefits in chronic heart failure, but its impact on cardiovascular reactivity to laboratory stressors remains unknown.
Does device-guided slow breathing improve cardiovascular reactivity to stress and quality of life in patients with HFrEF?
Does device-guided slow breathing improve cardiovascular reactivity to stress and quality of life in patients with HFrEF?
Device-guided slow breathing may reduce cardiovascular reactivity to mental stress and improve quality of life in patients with severe HFrEF on optimal medical therapy.
Answers are grounded in this paper and cite their sources.
May blunt hemodynamic reactivity to stressors and improve QoL in stable HFrEF; leaves open effects on clinical outcomes.
BACKGROUND: Previous studies have demonstrated therapeutic benefits of slow breathing (SLOWB) in chronic heart failure (HF) but its impact on cardiovascular reactivity in response to laboratory stressors remains unknown. METHODS: Using device-guided breathing this study explored the acute and long-term effects of SLOWB on hemodynamic responses to handgrip, mental and cold pressor tests, and health-related quality of life (QoL) in stable HF patients with reduced ejection fraction (HFrEF) who had received all available optimal drug and device therapies. Blood pressure (BP) and heart rate (HR) were measured in 21 patients with HFrEF (23.9 ± 5.9%) at rest, during laboratory stressors, before and after acute SLOWB, and 12 weeks after SLOWB home training (30 min daily). Health-related QoL (MacNew questionaries) was assessed before and 12 weeks after SLOWB home training. RESULTS: Resting BP significantly increased in response to three laboratory stressors. Pressor and cardiac changes during mental stress were greater than responses to the handgrip test (p < 0.05). Mental stress also produced a greater HR change than cold pressor test (p < 0.05). Both acute and long-term SLOWB significantly reduced BP and HR responses to mental stress (p < 0.05), but not to isometric and cold pressor tests. SLOWB improved scores of all domains of QoL (p < 0.05) at 12 weeks follow-up. CONCLUSIONS: These findings demonstrate that SLOWB reduces acute and chronic effects of cardiovascular reactivity to mental stress and improves various aspects of health-related QoL in patients with severe HFrEF. Whether stress reduction and psychological changes achieved with SLOWB may translate to improved outcomes in HFrEF warrants further exploration.
No takes yet. Share an insight, caveat, or question.
Lachowska et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: